The contribution of alternative RNA splicing in the progression of pancreatic ductal adenocarcinoma (PDAC) has not been deeply explored. In a recent study, the RNA-binding protein RNA binding fox-1 homolog 2 (RBFOX2) was investigated, since its role in modulating alternative splicing in PDAC is not well understood.
Saniona AB has selected its proprietary GABA-A α5 negative allosteric modulator lead compound, SAN-2465, as a clinical candidate for major depressive disorder following encouraging results in a rodent model.
Recent studies have identified 70 oxygenized phosphatidylcholine (PC)-containing epoxy and hydroperoxide groups that are generated in the early phase of acetaminophen (APAP)-induced acute liver injury. In a new study, researchers from the University of Tokyo focused on arachidonate PC and assessed the role of liver-specific LPCAT3 (lysophospholipid acyltransferase 3) on APAP-induced acute liver injury in mice.
JAK1 signaling promotes skin inflammation and is a major therapeutic target for atopic dermatitis-related itching. But in a study appearing in the Jan. 4, 2024, print issue of Cell after earlier publication online, researchers at the Icahn School of Medicine at Mount Sinai, led by dermatologist Brian Kim, found that intrinsic JAK1 signaling in sensory neurons had an immunoprotective effect in the lung. The findings suggest a more precise and personalized approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders.
Kinoteck Therapeutics Co. Ltd. have prepared and tested new ribosomal protein S6 kinase alpha-3 (RSK-2; MAPKAPK-1b) inhibitors potentially useful for the treatment of cancer.
Biocells (Beijing) Biotech Co. Ltd. has patented isoquinolinone derivatives acting aquaporin-4 (AQP4) inhibitors and thus reported to be useful for the treatment of hypervolemia (fluid overload) and cerebral ischemia.
Work at Zhuhai Yufan Biotechnologies Co. Ltd. has led to the development of proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety.
Janssen R&D (Ireland) has identified compounds acting as viral fusion inhibitors and reported to be useful for the treatment of respiratory syncytial virus (RSV) infections.
RSS
